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Original Article
Assessment of the clinical relevance of quantitative sensory
testing with Von Frey monofilaments in patients with
allodynia and neuropathic pain. A pilot study
D. Keizer*, M. van Wijhe*, W. J. Posty, D. R. A. Ugesz, J. M. K. H. Wierda*
University Medical Center Groningen, *Pain Management Center, Department of Anesthesiology; yOffice for Medical
Technology Assessment; zDepartment of Pharmacy, The Netherlands
Summary
Background: Allodynia is a common and disabling symptom in many patients with neuropathic pain. Whereas
quantification of pain mostly depends on subjective pain reports, allodynia can also be measured objectively
with quantitative sensory testing. In this pilot study, we investigated the clinical relevance of quantitative
sensory testing with Von Frey monofilaments in patients with allodynia as a consequence of a neuropathic pain
syndrome, by means of correlating subjective pain scores with pain thresholds obtained with quantitative
sensory testing. Methods: During a 4-week trial, we administered a cannabis extract to 17 patients with
allodynia. We quantified the severity of the allodynia with Von Frey monofilaments before, during and after
the patients finished the trial. We also asked the patients to rate their pain on a numeric rating scale at these
three moments. Results: We found that most of the effect of the cannabis occurred in the last 2 weeks of the
trial. In this phase, we observed that the pain thresholds, as measured with Von Frey monofilaments, were
inversely correlated with a decrease of the perceived pain intensity. Conclusion: These preliminary findings
indicate clinical relevance of quantitative sensory testing with Von Frey monofilaments in the quantification
of allodynia in patients with neuropathic pain, although confirmation of our data is still required in further
studies to position this method of quantitative sensory testing as a valuable tool, for example, in the evaluation
of therapeutic interventions for neuropathic pain.
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Introduction
In many patients with neuropathic pain, the pre-
sence of allodynia can be observed [1–3]. Allodynia,
defined by the International Association for the
Study of Pain (IASP) as pain caused by a stimulus
that would not normally evoke pain, can be
demonstrated when, for example, lightly rubbing
the affected skin is found to be painful [4]. It is a
very disabling physical symptom that frequently
co-occurs with hyperalgesia in neuropathic pain
syndromes [5,6]. Allodynia can be produced by the
action of low threshold Ab-fibres on an altered
central nervous system, but it may also be the
consequence of hyperexcitation of nociceptor term-
inals in the periphery [2]. To determine the exact
underlying pathophysiological mechanisms of a
patient’s allodynia is difficult if not impossible in
clinical practice.
As stimulus-independent pain is always sub-
jective; evaluation of the efficacy of analgesic
treatment thus depends on a subjective effect size,
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such as a visual analogue scale or numeric rating
scale (NRS). This single-dimension subjective
scaling does not differentiate between sensory and
affective components of pain and addresses the
complex nature of the experience as a whole [7,8].
In patients with neuropathic pain, the presence of
stimulus-dependent pain, such as allodynia, can be
used to evaluate the sensory-discriminative aspects
of pain more specifically with quantitative sensory
testing (QST). QST can thus be used to evaluate
treatment outcome more objectively [9].
Methods for the quantification of stimulus-
dependent pain should ideally be simple to execute
and yield standardized, validated and reproducible
results [10]. Furthermore, the method used should
be clinically relevant.
In this pilot study, we investigated the clinical
relevance of QST with Von Frey monofilaments in
patients suffering from allodynia as a consequence of
a neuropathic pain syndrome. Despite its hetero-
geneity, the clinical symptom allodynia can be
quantified within a narrow range of deviation using
Von Frey monofilaments [11]. Importantly, QST
with Von Frey monofilaments is simple in clinical
practice and yields reliable and reproducible results
[12,13]. We calculated the correlation between a
change in the clinical pain (NRS) and changes in
QST responses during a therapeutic intervention
(see below). A relation between an improvement of
the perceived pain and an increased pain threshold
would imply clinical relevance of QST with the
monofilaments [9].
In order to achieve intra-individual variation of
the intensity of allodynia, we chose to administer
a whole-plant cannabis extract to the patients.
Cannabis has been shown to improve allodynia and
hyperalgesia in animal studies and in one study
with experimental neuropathic pain in human
beings [14–17]. During a 4-week period, we
administered this cannabis extract to 17 patients
who suffered from allodynia as a consequence of a
unilateral neuropathic pain syndrome.
Methods
Twenty patients suffering from unilateral neuro-
pathic pain and allodynia participated in this study
after giving their informed consent. The study was
approved by the Medical Ethics Committee of the
University Medical Center Groningen. In these
patients, history and physical examination revealed
the presence of neuropathic pain and allodynia.
Neuropathic pain was diagnosed in all the patients,
as there was no tissue damage or nociception that
caused the pain, the pain was located in the dis-
tribution area of specific nerves or in one or more
dermatomes and there was stimulus-dependent
pain. Allodynia was diagnosed when light stroking
of the skin was reported as painful on the affected
skin.
Patients suffering from polyneuropathy or dia-
betes mellitus were excluded, as those conditions are
associated with hypoesthesia and may subsequently
influence the outcome of QST. Drug addiction and
psychiatric conditions were also considered as
exclusion factors. All patients were Caucasian;
Dutch was their native language. The patients
continued their usual (analgesic) medication and
they and their doctors were asked not to change
medication or dosage without consulting one of the
members of our research team.
During the first visit (T0), the procedure was
explained, QST with Von Frey monofilaments was
performed and 3 g of whole-plant cannabis were
given in three separate envelopes. The patients were
instructed to suspend a tea ball containing 1 g of
cannabis for 20min in 1 L of boiling water. Each
night, just before sleeping, the patients drank
200mL of this tea. They were free to choose
whether they preferred the tea warm or cold, and
with or without sugar or milk. The remaining tea
was preserved in the refrigerator.
Two weeks later (T1), the patient was asked if he
had noticed any effects caused by the use of cannabis,
either analgesia or side-effects. If the patient had not
noticed any effect, the dose was doubled, which meant
an extra cup of cannabis-tea to be taken each morning.
QST with Von Frey monofilaments was then per-
formed, as well as at the end of the trial 2 weeks later
(T2), when the cannabis was discontinued.
Experimental setting
All patients underwent the measurements in a quiet
room with a constant temperature of 20–228C. Each
of the examination was carried out by the same
investigator (D.K.). To acclimatize, the patients
were present in the room for about 10min prior to
the actual investigation. During this time, the
patients were informed about the procedure and
the monofilaments were demonstrated to familiarize
the patients with the procedure. Subsequently, the
patients were investigated while lying comfortably
on an examination table.
The patient was asked to point out the skin area
where allodynia was perceived as most intense. The
punctum maximum of the allodynia was marked
with a little square (61 cm2) drawn on the skin.
The corresponding spot on the contralateral side of
the body was marked similarly. These locations were
documented in the patient’s medical record for the
subsequent measurements 2 and 4 weeks later.
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Subjective pain scores
The patient was asked to indicate the severity of the
pain of that moment on a NRS, which implied that
the patient attributed a number to the perceived
pain on the affected skin, ranging from 0 (no pain)
to 10 (worst pain imaginable).
Quantitative sensory testing
A kit consisting of 20 nylon Von Frey monofila-
ments with increasing diameter of the firm Touch
TestTM (North Coast Medical, Inc., Morgan Hill,
LA, USA) was used for QST. When applied on the
skin, monofilaments exert a constant force, as the
monofilament bends. This bending reduces mea-
surement outcome artifacts resulting from move-
ment or trembling of the examiner’s hand [12].
The monofilaments are calibrated in a logarith-
mic scale from 0.008 to 300 g (0.08–2943mN),
within a 5% standard deviation (SD). Numbers on
each monofilament ranging from 1.65 to 6.65,
represent the common logarithm of 10 times the
force in milligrams [18].
The monofilaments were applied in increasing
thickness (method of limits) on the affected and non-
affected side successively, in a randomized sequence,
until a pain threshold was detected. The patient was
asked to give a clear verbal signal when the stimulus
was perceived to be painful. Each monofilament was
applied three times, with approximately 10 s
between two successive stimuli, to avoid temporal
summation [19,20]. Subsequently, the procedure
was repeated on the contralateral side.
The monofilament was applied perpendicularly
to the skin surface for approximately 2 s, until a
bending of 3–5mm of the monofilament was pro-
duced. Patients kept their eyes closed during the
investigation to avoid visual feedback concerning
the stimuli.
The pain threshold was defined as the logarith-
mic number on the monofilament in which at least
two out of three applications on the affected side
resulted in the perception, and subsequent report-
ing of pain, the so-called ‘appearance’ threshold
[10,21]. Once a pain threshold was reached, QST
was stopped. QST of the unaffected side was also
performed to obtain baseline values.
The duration of the procedure was 10–15min.
We assumed that no significant loss of attention
occurred during this procedure.
Cannabis extract
We used standardized whole plant cannabis pro-
duced by the firm Maripharms (Rotterdam, The
Netherlands). This cannabis has been sterilized for
microbial contamination by means of gamma-
irradiation. According to European Pharmacopoeia
requirements, the cannabis contains an acceptably
small quantity of pesticides and metalloids. In our
hospital’s department of pharmacy, we measured the
tetrahydrocannabinol (THC), cannabinol (CBN)
and cannabidiol (CBD) contents in the cannabis (18
samples) and the extract (six samples) by a validated
GC–MS method. The mean concentration for THC
in the cannabis was 6%6 0.9% (mean6 SD) and in
the cannabis-extracts 1%6 0.2% (mean6 SD).
CBN and CBD were found neither in the tea bags
nor in the extract.
Statistical analysis
For the subjective NRS scores as well as the pain
thresholds measured with the monofilaments, dif-
ference scores were calculated between the various
time points (T0, T1 and T2). To investigate the
relation between the change in pain thresholds and
the change in NRS scores, two-tailed Pearson cor-
relation coefficients were calculated.
For all statistical calculations in this study,
P-values smaller than 0.05 were considered statis-
tically significant.
Results
Baseline characteristics of the patients
Initially, the selected group of patients consisted of
six males and 14 females. Three patients were lost
to follow-up; one because of the development of
oedema in both legs and two other patients because
of insufficient ability to co-operate. The data of
the remaining 17 patients (five males, 12 females)
were analysed. Their mean age was 47.1 yr (range
27–61 yr). The duration of their underlying pain
syndromes varied strongly and differed from only a
few months to several decades (see Table 1). The
neuropathic pain was either the result of surgery
[12], trauma [2], stroke [1] or had a (pseudo)-radi-
cular origin [2].
At the time of inclusion, five patients did not use
any medication, two patients used a non-steroidal
anti-inflammatory drug and 10 patients used a
tricyclic antidepressant and/or an antiepileptic
drug, sometimes in combination with other
analgesic drugs (Table 1).
Subjective effects and side-effects
At T1, two of the 17 participating patients indi-
cated to perceive less pain and experienced an
improved sense of well-being. In these patients, the
dose was not increased. In the remaining 15 patients
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the dose was increased, as they described no sub-
jective effect of the cannabis at that moment.
None of the patients that enrolled in this study
dropped out because of side-effects. In most patients
(15/17), no side-effects occurred at all. However,
when side-effects did occur (2/17), they were con-
sidered as mild by the participating patients. One
patient described a mild transitory redness of the
eyes; the other patient had experienced a mild
dizziness. Seven patients described an improved
sense of well being after completing the trial.
I: Quantitative sensory testing and subjective pain
report
T1–T0: For the first 2 weeks of the study, the
correlation between the change in pain thresholds
and the change in subjective pain scores was 0.008
(P5 0.976), indicating no relation between the
measured difference in pain thresholds and the
difference in the reported pain.
T2–T0: For the whole 4-week period, the corre-
lation between the change in pain thresholds and
the change in subjective pain scores was 20.426
(P5 0.088).
T2 –T1: During the last 2 weeks of the study,
the correlation between the change in pain thresh-
olds and the change in subjective pain scores was
20.501 (P5 0.040) indicating a relation that is
statistically significant (see Fig. 1a–c).
On the contralateral, unaffected side, no pain
threshold could be determined in 16 of the 17
patients at any time in the study. One patient,
with postoperative neuropathic pain as a result of
Table 1. Characteristics of included patients: age, gender, diagnosis, duration of pain and medication use are displayed.
Patient no. Age (yr) Sex Neuropathic pain due to
Duration of
pain (months) Use of medication
1 52 F Surgery 60 None
2 37 F Surgery 5 None
3 27 F Surgery 100 Ibuprofen
4 56 M (Pseudo)-radicular irritation 22 None
5 54 M Surgery 72 Gabapentin
6 41 M Surgery 300 None
7 56 F Surgery 54 Amitriptyline
8 56 F Surgery 19 Gabapentin, Tramadol
9 43 F Surgery 54 Amitriptyline
10 45 F Stroke following head trauma 25 Gabapentin
11 48 F Trauma 30 Gabapentin
12 59 F Surgery 65 Naproxen, tramadol
13 52 F Surgery 60 Morphine
14 31 F Surgery 15 Amitriptyline, paracetamol, codeine,
gabapentin
15 37 M Trauma 10 Gabapentin, tramadol
16 46 F (Pseudo)-radicular irritation 35 Amitriptyline
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In the first 2 weeks of the trial no relation between the pain thresholds and subjective pain scores was observed (a). During the last 2 weeks of
the trial, the increase in pain threshold correlated significantly with a decreased NRS-score (c). The correlation that was calculated for the
whole 4-week period did not reach statistical significance (b). (NRS: numerical rating scale).
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paramedian abdominal surgery, also experienced the
application of thick Von Frey monofilaments on the
contralateral healthy skin as painful. She rated her
pain of the affected skin to be 10 on the NRS on T0,
T1 and T2.
Discussion
Pain is always subjective [4]. The subjective
nature of pain poses a problem on pain researchers
and clinicians involved in the treatment of pain on
how to quantify pain in order to evaluate ther-
apeutic interventions as objectively as possible.
In the case of neuropathic pain, concomitant
symptoms such as allodynia and hyperalgesia can be
used to quantify the severity of the pain by means
of QST [9].
Our pilot study indicated clinical relevance of
QST with monofilaments of allodynia in patients
suffering from neuropathic pain, since the measured
pain threshold is negatively associated with a
decrease in the perceived pain intensity. These
results are in agreement with other studies in which
a relation between QST responses and clinical pain
was found [9,22].
Several aspects of this study need further con-
sideration. With respect to terminology, we used
the IASP definitions of allodynia and hyperalgesia
in this study. We realize that many authors use the
term ‘punctate hyperalgesia’ to indicate the pain
following the application of Von Frey monofila-
ments. However, we did not use the word ‘hyper-
algesia’ since the application of the monofilaments
on unaffected skin was not considered painful by the
control subjects and in all patients except one. We
therefore preferred the term ‘allodynia’.
We chose to use a cannabis-extract to influence
the severity of the patients’ allodynia, as animal
studies show that cannabinoids are capable of
decreasing the intensity of certain types of stimulus
dependant pain, i.e. hyperalgesia and allodynia. In
rats, low dose cannabinoids are even capable of
reducing allodynia and hyperalgesia, without pro-
ducing unacceptable side-effects [15,16,23,24]. In
human subjects, the topically administered syn-
thetic cannabinoid agonist HU210 attenuated cap-
saicin-induced touch-evoked allodynia [17]. Of all
cannabinoids, the efficacy of (D9-)THC against
allodynia and hyperalgesia has been studied most
extensively. In order to change the patients’ allo-
dynia we needed to use a THC-containing cannabis-
extract.
Three patients were lost to follow-up during the
study. One female patient was excluded during the
trial, because of aggravation of pre-existing oedema
in both legs that influenced sensory function. She
was referred back to her General Practitioner for
diagnostic work-up. Two other patients were
excluded due to insufficient co-operation. One of
these patients failed to comply with the protocol
due to hypochondriasis, while the other patient was
unable to produce the cannabis-extract adequately.
The latter is an obvious disadvantage in general;
although not difficult, the complexity of this pro-
cedure can lead to mistakes.
As stated earlier, a relation between an
improvement of the clinical pain and an increased
pain threshold would imply clinical relevance of
QST with the monofilaments. In this study, we
found a clear increase of the pain thresholds,
however, the decrease of the clinical pain was not
statistically significant. Probably, the number of
patients that participated in this study was too
small, or the quantity of ingested cannabinoids may
have been inadequate, to detect this effect. The
change in pain thresholds – as measured with the
Von Frey monofilaments – and NRS scores, pre-
dominantly occurred in the last 2 weeks of the trial
(see below). It was in this period (T2–T1) that we
found a statistically significant correlation between
QST responses and pain report.
Our finding that the change in pain thresholds
and pain report mainly occurred in the last 2 weeks
of the trial, may be explained by a delayed efficacy of
the cannabis. Another possibility that cannot be
ruled out is habituation to the testing procedure.
However, we regard the latter possibility to be
unlikely, since the patients had been familiarized
with the testing procedure prior to the actual study.
Furthermore, the measurements took place only three
times in total, with 2-week intervals. A delayed
efficacy of cannabis as an explanation for the change
in pain thresholds and pain report is more likely,
and may be caused by rapid redistribution of can-
nabinoids in the body. As a consequence, an effective
plasma level of THC is reached only after repeated
dosage. Cannabinoids have a long elimination
half-life of up to multiple days, due to extensive
uptake in the fatty tissues from where slow release
takes place [25]. In comparison, many drugs with a
known analgesic effect against neuropathic pain, e.g.
tricyclic antidepressants, also exert a therapeutic
effect with a delayed onset of a few days to several
weeks [1]. Finally, the placebo-effect may also
account for the change in pain thresholds and
pain report, as no control group was included in
this study.
In conclusion, we demonstrated that an increased
pain threshold correlated significantly with a
decreased report of pain in this pilot study. These
preliminary findings suggest that QST with Von
Frey monofilaments is a clinically relevant method
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in patients with allodynia and neuropathic pain,
although larger studies are needed for further proof.
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